Yes and if COVID-19 in Spain was in fact the issue, then Anavex should have disclosed that at the time when the impact to trial was known instead of n=20 at readout. And that regardless of the BSIG 'explanation'.
It does not help the credibility of Anavex to leave investors, and this message board, expecting some 90% of the trial patients completing the OLE study.
There have been several posts here, including from you, on all the amazing data we would get to know about from that OLE study. But now of course the WGT lot can easily find all the lame apologies to cover for their own surprise and disappointment.
Anavex has developed into a new version of Peter and the Wolf story, who the market won't trust to tell the truth.
News 
Market Data 
Discover 
